Distribution of Pneumococcal Serotypes and Vaccine Coverage in US Pneumococcal Disease

Overview

This study assessed the distribution of pneumococcal serotypes causing invasive pneumococcal disease (IPD) and acute respiratory infections (ARIs) in the US, evaluating coverage by current and pipeline pneumococcal conjugate vaccines (PCVs). Findings indicate that newer PCVs with expanded valency, such as PCV31, cover a substantially higher proportion of pneumococcal disease burden compared to earlier vaccines like PCV15.

Background

Streptococcus pneumoniae causes both invasive diseases (e.g., bacteremia, meningitis) and noninvasive acute respiratory infections including acute otitis media (AOM), sinusitis, and nonbacteremic pneumonia. Over 100 pneumococcal serotypes exist, but only a subset cause most human disease. Pneumococcal conjugate vaccines (PCVs) have evolved from 7-valent to 13-valent and now to higher valency formulations to address serotype replacement and broaden protection. Understanding serotype distribution in both invasive and noninvasive disease is crucial for guiding vaccine policy and development.

Data Highlights

Key Findings

• PCV15 serotypes account for 16% of pediatric AOM and 43% of adult nonbacteremic pneumonia cases.
• Expanded valency vaccines such as PCV31 cover up to 68% of pediatric AOM and 87% of adult nonbacteremic pneumonia cases.
• Between 42% and 85% of pediatric IPD and 42% to 94% of adult IPD cases are caused by serotypes included in current or pipeline PCVs.
• Annual US pneumococcal disease burdens potentially preventable by PCVs range from hundreds of thousands of outpatient ARIs to thousands of pneumonia hospitalizations and IPD cases.
• PCV21 shows substantial coverage of adult pneumococcal disease, highlighting its potential role in adult vaccination strategies.
• Vaccine-induced serotype replacement necessitates ongoing PCV reformulation to maintain and improve coverage.

Clinical Implications

The findings support the use of higher-valency PCVs to broaden protection against pneumococcal disease in both children and adults. Clinicians should consider evolving vaccine recommendations as newer PCVs become available, especially for populations at increased risk of pneumococcal infections. Surveillance of serotype distribution remains essential to guide vaccine policy and optimize prevention strategies.

Conclusion

Expanded-valency pneumococcal conjugate vaccines substantially increase coverage of pneumococcal disease serotypes causing both invasive and noninvasive infections. These data inform vaccine policy decisions aimed at reducing the substantial pneumococcal disease burden in the United States.

References

1. Author/Source/Year -- Distribution of Pneumococcal Serotypes and Evaluation of Current and Upcoming Pneumococcal Vaccines' Coverage